Illumina (NASDAQ:ILMN) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Illumina (NASDAQ:ILMN) announced its quarterly earnings data on Thursday. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08, FiscalAI reports. Illumina had a net margin of 18.36% and a return on equity of 30.54%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the previous year, the company posted $1.19 EPS. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Illumina’s conference call:

• Q2 exceeded expectations: Revenue rose 9.5% year over year to $1.16 billion, organic rest-of-world growth was 8.1%, and non-GAAP EPS increased 10% to $1.31. Operating margin also came in above guidance despite higher freight and memory costs.
• Clinical demand remains the primary growth engine, with clinical sequencing consumables up 15% outside China and U.S.-Canada growth above 20%. Illumina placed more than 95 NovaSeq X instruments in the quarter, expanding the installed base and supporting future consumables pull-through.
• Management raised full-year 2026 guidance to rest-of-world organic revenue growth above 5%, reported revenue of $4.60 billion-$4.64 billion, and non-GAAP EPS of $5.30-$5.40. The company continues to target high-single-digit revenue growth in 2027.
• Research and academic customers remain cautious amid funding uncertainty; research and applied consumables declined 7% in the quarter, and Illumina still expects mid- to high-single-digit declines in this market for 2026.
• Illumina is expanding beyond core sequencing through spatial biology, proteomics, and BioInsite. The Billion Cell Atlas has delivered more than 300 million cells, generated initial revenue, and added three partners after quarter-end, bringing the total to six, although management characterized the opportunity as still early.

Illumina Stock Up 0.0%

NASDAQ:ILMN traded up $0.01 on Friday, hitting $205.10. 4,099,445 shares of the company’s stock traded hands, compared to its average volume of 1,637,936. The company has a market cap of $31.03 billion, a PE ratio of 38.26, a price-to-earnings-growth ratio of 3.03 and a beta of 1.47. Illumina has a 1 year low of $88.00 and a 1 year high of $205.93. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $176.70 and a 200-day moving average price of $147.24.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Analysts Set New Price Targets

Several research firms have issued reports on ILMN. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. Barclays raised their price objective on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday. Leerink Partners lifted their target price on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Stifel Nicolaus boosted their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $175.47.

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 over the last ninety days. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Toronto Dominion Bank lifted its holdings in shares of Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after buying an additional 92 shares during the last quarter. Panagora Asset Management Inc. raised its position in Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares in the last quarter. Parallel Advisors LLC raised its position in Illumina by 4.7% during the third quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock valued at $269,000 after acquiring an additional 128 shares in the last quarter. Zacks Investment Management lifted its stake in Illumina by 0.6% in the third quarter. Zacks Investment Management now owns 24,655 shares of the life sciences company’s stock valued at $2,342,000 after acquiring an additional 143 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in Illumina by 8.8% in the fourth quarter. UMB Bank n.a. now owns 1,943 shares of the life sciences company’s stock valued at $255,000 after acquiring an additional 157 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.